99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI

Objectives Posttherapy changes in treated glioma patients cannot be reliably differentiated from tumor recurrence. We evaluated the role of 99mTc-methionine SPECT/CT for the detection of recurrent glioma and compared the same with 18F-FDG PET/CT and contrast-enhanced MRI (CeMRI). Methods Forty-four patients with histologically proven, previously treated glioma and clinical suspicion of recurrence were prospectively enrolled in the study. Of these 44 patients, 39 (28 male and 11 female subjects; age, 38.05 ± 9.7 years) underwent 99mTc-methionine SPECT/CT, 18F-FDG PET/CT, and CeMRI of the brain and were included for final analysis. Combination of repeat imaging, biopsy, and/or clinical follow-up (6–36 months) was taken as reference standard. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Diagnostic values among modalities were compared. Results Positive predictive value and negative predictive value for 99mTc-methionine SPECT/CT, 18F-FDG PET/CT, and CeMRI were 95.6% and 56.2%, 92.3% and 61.5%, and 79.4% and 42.9%, respectively. Sensitivity and specificity for the 3 modalities were 75.9% and 90%, 82.8% and 80%, and 87.1% and 30%. Specificity of 99mTc-methionine SPECT/CT was significantly higher than that of CeMRI (P

https://ift.tt/2qsfa5l